Soleus Capital Management L.P. trimmed its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 68.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 75,405 shares of the company's stock after selling 164,300 shares during the period. Soleus Capital Management L.P. owned about 0.15% of Enliven Therapeutics worth $1,697,000 as of its most recent SEC filing.
A number of other institutional investors also recently made changes to their positions in the business. Invesco Ltd. raised its position in shares of Enliven Therapeutics by 3.5% in the 4th quarter. Invesco Ltd. now owns 15,072 shares of the company's stock valued at $339,000 after purchasing an additional 508 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Enliven Therapeutics by 3.7% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,036 shares of the company's stock valued at $451,000 after purchasing an additional 718 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Enliven Therapeutics by 230.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock valued at $36,000 after purchasing an additional 1,114 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Enliven Therapeutics by 14.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company's stock valued at $233,000 after purchasing an additional 1,275 shares in the last quarter. Finally, MetLife Investment Management LLC raised its position in shares of Enliven Therapeutics by 6.3% in the 4th quarter. MetLife Investment Management LLC now owns 21,746 shares of the company's stock valued at $489,000 after purchasing an additional 1,285 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
ELVN has been the topic of a number of recent analyst reports. HC Wainwright upped their target price on Enliven Therapeutics from $39.00 to $40.00 and gave the company a "buy" rating in a research report on Thursday, May 15th. Jones Trading lowered their price target on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a report on Friday, May 16th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $37.25.
View Our Latest Stock Report on ELVN
Enliven Therapeutics Stock Performance
Shares of NASDAQ ELVN traded down $0.37 during trading on Friday, reaching $16.40. The stock had a trading volume of 222,508 shares, compared to its average volume of 259,466. Enliven Therapeutics, Inc. has a one year low of $13.30 and a one year high of $30.03. The stock has a market cap of $804.73 million, a PE ratio of -8.63 and a beta of 1.07. The firm's 50 day moving average price is $18.46 and its two-hundred day moving average price is $21.36.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). On average, research analysts expect that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.
Insider Buying and Selling
In related news, COO Anish Patel sold 6,667 shares of the company's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $21.44, for a total transaction of $142,940.48. Following the completion of the transaction, the chief operating officer now directly owns 323,310 shares in the company, valued at $6,931,766.40. This represents a 2.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Samuel Kintz sold 12,500 shares of the company's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $20.83, for a total value of $260,375.00. Following the transaction, the chief executive officer now owns 990,392 shares of the company's stock, valued at approximately $20,629,865.36. The trade was a 1.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 86,111 shares of company stock worth $1,657,145 in the last three months. 29.20% of the stock is owned by insiders.
Enliven Therapeutics Company Profile
(
Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
See Also
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
